News | May 11, 2010

PET Improves Prognosis in Locally Advanced Breast Cancer

May 11, 2010 - An aggressive weekly preoperative regimen of positron emission tomography (PET) significantly improved distant metastasis-free and overall survival in patients with highly aggressive breast tumors.

Patients in the randomized Italian SICOG 9908 trial had locally advanced breast cancer. The disease break down as follows: 136 patients had T4a-c disease, 47 had inflammatory breast cancer and 17 had N2 breast cancer.

Patients underwent 12 weekly cycles of PET (cisplatin, epirubicin, paclitaxel), compared with four tri-weekly cycles of epirubicin and paclitaxel (ET), given preoperatively to women with locally advanced breast cancer.

The researchers found distant metastasis-free survival (DMFS) at five years was significantly better in the PET patients (73 vs. 55 percent; P = .037). PET also significantly improved elapse-free survival (RFS) rates in patients with grade 3 tumors.

The 12-week therapy improved both DMFS and overall survival (OS) in patients with locally advanced breast cancer, over the survival outcomes attained with four triweekly cycles of ET.

The study showed that patients receiving PET had a significantly lower risk of distant metastasis and death.

The authors stated: “These data confirm that patients with inflammatory disease should not have breast-conserving therapy. Further, stage three B patients should have an accurate initial work-up, including (Fludeoxyglucose) FDG-PET and dynamic magnetic resonance imaging, to rule out occult and distant metastases.”

They also noted, “irradiation of both internal mammary and supraclavicular nodal regions should be mandatory in patients with stage three B disease at diagnosis, regardless of their pathologic response to neoadjuvant chemotherapy.”

Reference: Frasci, G., D'Aiuto, G., et al. “Preoperative Weekly Cisplatin, Epirubicin, and Paclitaxel (PET) Improves Prognosis in Locally Advanced Breast Cancer Patients: An Update of the Southern Italy Cooperative Oncology Group (SICOG) Randomised Trial 9908.” Ann Oncol. 2010 Apr 1;21(4):707-716. Southern Italy Cooperative Oncology Group, Italy.

For more information:

Related Content

Researchers Trace Parkinson’s Damage in the Heart
News | PET Imaging | July 17, 2018
A new way to examine stress and inflammation in the heart will help Parkinson’s researchers test new therapies and...
Siemens Healthineers Announces FDA Clearance of syngo.via VB30 Molecular Imaging Software
Technology | Nuclear Imaging | July 16, 2018
At the 2018 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), June 23-26 in Philadelphia...
SNMMI Image of the Year Highlights Theranostic Approach for Advanced Prostate Cancer

IMAGE OF THE YEAR: PSMA PET before and after lutetium-177 PSMA617 theranostics in 8 patients with metastatic prostate cancer who exhausted standard therapeutic options.

68Ga-PSMA11 PET maximum intensity projection (MIP) images at baseline and 3 months after 177Lu-PSMA617 in 8 patients with PSA decline ≥ 98 percent in a prospective phase II study. Any disease with SUV over 3 is in red. Credit: Michael Hofman, John Violet, Shahneen Sandhu, Justin Ferdinandus, Amir Iravani, Grace Kong, Aravind Ravi Kumar, Tim Akhurst, Sue Ping Thang, Price Jackson, Mark Scalzo, Scott Williams and Rodney Hicks, Peter MacCallum Cancer Centre, Melbourne, Australia.

News | PET Imaging | June 29, 2018
In the battle against metastatic castrate-resistant prostate cancer, studies have demonstrated a high response rate to...
MILabs Introduces Futuristic PET Capabilities on New VECTor6 System
Technology | PET Imaging | June 28, 2018
At the 2018 Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting, June 23-26, in Philadelphia,...
Philips North America and GE Healthcare Win IMV PET Imaging ServiceTrak Awards
News | PET Imaging | June 25, 2018
IMV, part of the Science and Medicine Group and a market research and business intelligence provider to the imaging...
FDA Clears New Imaging Functionalities for Biograph mCT PET/CT Systems
Technology | PET-CT | June 21, 2018
Siemens Healthineers will announce U.S. Food and Drug Administration (FDA) clearance of four new system features for...
PET/CT Changes Care for 59 Percent of Suspected Recurrent Prostate Cancer Cases
News | Prostate Cancer | June 13, 2018
A recently presented investigational clinical trial evaluated the impact of 18F fluciclovine positron emission...
News | Computed Tomography (CT) | May 21, 2018
The Istituto Oncologico Veneto (IOV) in Padua, Italy, has acquired MILabs’ latest-generation Versatile Emission...
PET Imaging Agent Could Provide Early Diagnosis of Rheumatoid Arthritis

Coronal 18F-FEDAC PET/CT section of a mouse with collagen-induced arthritis. (A) On day 23 and day 37, increased uptake is noted in the front and hind paws of this mouse with collagen-induced arthritis. (B) Predictive performance of day 23 18F-FEDAC uptake for the development of clinical arthritis. ROC = receiver operating characteristic; Sn = sensitivity; Sp = specificity. Credit: Seoul National University and Ewha Womans University, Seoul, South Korea

News | PET Imaging | May 17, 2018
A novel positron emission tomography (PET) tracer developed by Korean researchers can visualize joint inflammation and...
PET Imaging Shows Protein Clumping May Contribute to Heart Failure Development
News | PET Imaging | May 11, 2018
A team led by Johns Hopkins University Researchers has discovered that protein clumps appear to accumulate in the...
Overlay Init